Showing results (2311-2320 of 10,003) with videos related to
Sort By:
Pageof 1,001
Leukemia & Lymphoma|May 6, 2021
Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naïve chronic lymphocytic leukemiaMatthew S Davids, Claire Telford, Sarang Abhyankar, et al.Leukemia & Lymphoma|June 11, 2020
The paradoxical prognostic role of 1q21 Gain/Amplification in multiple myeloma: every coin has two sidesJiadai Xu, Tianhong Xu, Yang Yang, et al.Leukemia & Lymphoma|June 12, 2020
Dissecting factors influencing response to CAR T cell therapy in B lymphoid hematologic malignancies: from basic to practiceKitsada Wudhikarn, Jae H ParkLeukemia & Lymphoma|June 13, 2020
Primary prophylaxis with pegfilgrastim in patients with newly-diagnosed diffuse large B-cell lymphoma: propensity score and instrumental variable analysesKensuke Matsuda, Jo Taisuke, Masashi Miyauchi, et al.Leukemia & Lymphoma|February 6, 2023
Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary diseaseKhaled Sanber, Kevin Ye, Hua-Ling Tsai, et al.Leukemia & Lymphoma|November 12, 2022
Adherence to quality indicators in chronic myeloid leukemia care: results from a population-based study in The NetherlandsGeneviève I C G Ector, Inge G P Geelen, Avinash G Dinmohamed, et al.Leukemia & Lymphoma|November 12, 2022
Real-world assessment of the treatment patterns and outcomes among patients with multiple myeloma across different risk stratification criteria in the United States: a retrospective cohort studyMotiur Rahman, Alissa Keegan, Jazmine Mateus, et al.Leukemia & Lymphoma|August 20, 2021
Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitorPhilipp Bernhard Staber, Wojciech Jurczak, Richard Greil, et al.Leukemia & Lymphoma|August 17, 2022
Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II studyAspasia Stamatoullas, Hervé Ghesquières, Pierre Feugier, et al.Leukemia & Lymphoma|August 17, 2022
CD38 as a multifaceted immunotherapeutic target in CLLAneel Paulus, Fabio Malavasi, Asher Chanan-KhanPageof 1,001